MedTrace Logo

Haplo-identical/Mismatched Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome

NCT01793675 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 116

Last updated 2015-04-29

No results posted yet for this study

Summary

Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the only curative treatment for myelodysplastic syndrome (MDS), especially for advanced MDS (blast \>5%). However, many patients cannot find an HLA-matched donor. haploidentical donor is an alternative stem cell source.

the study hypothesis: Haploidentical/mismatched hematopoietic stem cell transplantation can improve the survival of patients with myelodysplastic syndrome

Conditions

  • Advanced MDS Without Identical Sibling Donor

Interventions

PROCEDURE

transplant with haploidentical donor

patients with advanced MDS without identical sibling donor receive haploidentical transplant

Sponsors & Collaborators

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • xiaojun huang, M.D. · Peking University People's Hospital

Eligibility

Min Age
2 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Primary Completion
2012-12-31
Completion
2014-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01793675 on ClinicalTrials.gov